Ignite Creation Date:
2025-12-25 @ 1:31 AM
Ignite Modification Date:
2026-02-21 @ 6:00 AM
Study NCT ID:
NCT01347294
Status:
UNKNOWN
Last Update Posted:
2023-11-07
First Post:
2011-04-11
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Compare Two Different Sclerosing Agents in the Treatment of Venous Malformations
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'D001761', 'term': 'Bleomycin'}], 'ancestors': [{'id': 'D006020', 'term': 'Glycopeptides'}, {'id': 'D006001', 'term': 'Glycoconjugates'}, {'id': 'D002241', 'term': 'Carbohydrates'}, {'id': 'D010455', 'term': 'Peptides'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'FACTORIAL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 135}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'ACTIVE_NOT_RECRUITING', 'startDateStruct': {'date': '2011-08', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2023-11', 'completionDateStruct': {'date': '2025-06-30', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2023-11-02', 'studyFirstSubmitDate': '2011-04-11', 'studyFirstSubmitQcDate': '2011-05-03', 'lastUpdatePostDateStruct': {'date': '2023-11-07', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2011-05-04', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2023-11-30', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Intesity, frequency and type of pain.', 'timeFrame': '1 year', 'description': 'Pain will be measured before, during and after treatment. It will be asked about type, characteristics and intensity of pain. Using the Visual Analog Score 0-10, 0 beingno pain,10 being maximum pain, will be used in this matter.'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'conditions': ['Venous Malformation']}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to determine the effectiveness of bleomycin, fibrovein and bleomycin and fibrovein in the treatment of venous malformation.', 'detailedDescription': 'Patients with scanty symptoms from their vascular malformation can do well with conservative treatment and / or with aids and adaptations in daily life. Compression therapy (elastic stockings), pain medication and good counseling is adequate for many. Patients with significant symptoms, however, may require more invasive treatment. Previously, it was common with surgical removal, but serious sequelae and frequent recurrence after surgery resulted in caution. Today it is more common with intervention radiology treatment with injection of sclerosing agents into existing malformation. This type of therapy almost always requires repeated treatment sequences, sometimes over several months. Treatment aims to seal blood vessels in the malformation and / or make the patient as possible symptoms. Recurrence occurs frequently and there are many who are not completely free from symptoms. Many patients have chronic problems with pain, wounds, bleeding and / or they have a cosmetically disfiguring condition. Predicting the performance of a specific type of treatment can be very difficult.\n\nUntil now, there are some studies that have considered the effect of bleomycin / pingyangmycin (China) and ethanol in the treatment of vascular malformations. To our knowledge there is no prospective or retrospective studies that compare the efficacy and side effects of bleomycin and sodium tetradecyl sulfate (Fibrovein ™) in the treatment of VM.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'maximumAge': '80 Years', 'minimumAge': '12 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Clinical diagnosis of Venous malformation\n* Must be able to fill in questionary form\n* Must be able to sign informed consent form\n\nExclusion Criteria:\n\n* Kidney disease\n* Lung disease\n* Pregnancy or not willing to safe contraception\n* Allergy to Bleomycin or Fibrovein'}, 'identificationModule': {'nctId': 'NCT01347294', 'briefTitle': 'Compare Two Different Sclerosing Agents in the Treatment of Venous Malformations', 'organization': {'class': 'OTHER', 'fullName': 'Oslo University Hospital'}, 'officialTitle': 'Compare the Effect of Bleomycin and Tetradecyl Sodium Sulphate in the Treatment of Venous Malformations', 'orgStudyIdInfo': {'id': '1331TMF'}, 'secondaryIdInfos': [{'id': 'TMF1331', 'type': 'OTHER', 'domain': 'OsloUH'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Bleomycin + Fibrovein', 'description': '1\\) Fibrovein 3% foamed with air 50/ 50. Total volum injected is the same as volume of malfomation. Volume of malformation estimated by contrast media injection before sclerotherapy.\n\n2\\) wait 5 minutes\n\n3\\) Bleomycin 1000 iu / ml. Injected volume same as volume of Fibrovein foam.', 'interventionNames': ['Drug: Bleomycin + Fibrovein']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Bleomycin', 'description': 'Bleomycin 1000 iu/ ml. Total volum injected is the same as volume of malfomation. Volume of malformation estimated by contrast media injection before sclerotherapy.', 'interventionNames': ['Drug: Bleomycin']}, {'type': 'EXPERIMENTAL', 'label': 'Natrium Tetradecyl Sulphate (Fibrovein )', 'description': 'Fibrovein 3% foamed with air 50/ 50. Total volum injected is the same as volume of malfomation. Volume of malformation estimated by contrast media injection before sclerotherapy.', 'interventionNames': ['Drug: Fibrovein']}], 'interventions': [{'name': 'Bleomycin', 'type': 'DRUG', 'otherNames': ['Bleomycin Baxter'], 'description': 'Intralesional', 'armGroupLabels': ['Bleomycin']}, {'name': 'Fibrovein', 'type': 'DRUG', 'otherNames': ['Fibrovein S.T.D pharmaceutical products LTD'], 'description': 'Intralesional', 'armGroupLabels': ['Natrium Tetradecyl Sulphate (Fibrovein )']}, {'name': 'Bleomycin + Fibrovein', 'type': 'DRUG', 'otherNames': ['Bleomycin Baxter + Fibrovein pharmaceutical products'], 'description': 'Intralesional', 'armGroupLabels': ['Bleomycin + Fibrovein']}]}, 'contactsLocationsModule': {'locations': [{'zip': '0227', 'city': 'Oslo', 'country': 'Norway', 'facility': 'Oslo Universitetssykehus Rikshospitalet', 'geoPoint': {'lat': 59.91273, 'lon': 10.74609}}], 'overallOfficials': [{'name': 'Andreas Abildgaard, Phd', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Oslo Universitetssykehus, Rikshospitalet'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Oslo University Hospital', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Principal Investigator', 'investigatorFullName': 'Rune Andersen', 'investigatorAffiliation': 'Oslo University Hospital'}}}}